Ocular drug delivery: Molecules, cells, and genes

Canadian Journal of Ophthalmology

Volumn 42, Issue 3, 2007, Pages 447-454

  Liu, Xuyang ^a,b   Brandt, Curtis R ^a   Rasmussen, Carol A ^a   Kaufman, Paul L ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b SICHUAN UNIVERSITY   (China)

^c Department of Ophthalmology and Visual Sciences ^*  (United States)

Author keywords

Cells; Gene therapy; Molecules; Ocular diseases

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; DNA; POLYPEPTIDE; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; CELL ENCAPSULATION; CELL THERAPY; CONFERENCE PAPER; CYTOLOGY; GENE DELIVERY SYSTEM; GENE TARGETING; GENETIC TRANSFECTION; GLAUCOMA; HERPES SIMPLEX VIRUS; HUMAN; LENTIVIRINAE; MEDICAL EDUCATION; MOLECULAR BIOLOGY; NONHUMAN; RETINA DISEASE; RETINA MACULA DEGENERATION; RETINITIS PIGMENTOSA;

EID: 34250685723     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/I07-049     Document Type: Conference Paper

References (56)

1. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 2000;41: 961-4.
2. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinlone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-7.
3. Sakurai E, Nozaki M, Okabe K, Kunou N, Kimura H, Ogura Y. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest Ophthalmol Vis Sci 2003;44:4845-52.
4. Gilger BC, Salmon JH, Wilkie DA, et al. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest Ophthalmol Vis Sci 2006;47:2596-605.
5. Cruysberg LP, Nuijts RM, Gilbert JA, Geroski DH, Hendrikse F, Edelhauser HF. In vitro sustained human transscleral drug delivery of fluorescein-labeled dexamethasone and methotrexate with fibrin sealant. Curr Eye Res 2005;30:653-60.
6. MacLaren RE, Pearson RA, MacNeil A, et al. Retinal repair by transplantation of photoreceptor precursors. Nature 2006; 444:203-7.
7. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006;103:3896-901.
8. Takahashi M, Palmer TD, Takahashi J, Gage FH. Widespread integration and survival of adult-derived neural progenitor cells in the developing optic retina. Mol Cell Neurosci 1998;12: 340-8.
9. Banin E, Obolensky A, Idelson M, et al. Retinal incorporation and differentiation of neural precursors derived from human embryonic stem cells. Stem Cells 2006;24:246-57.
10. Hara A, Niwa M, Kumada M, et al. Intraocular injection of folate antagonist methotrexate induces neuronal differentiation of embryonic stem cells transplanted in the adult mouse retina. Brain Res 2006;1085:33-42.
11. Enzmann V, Howard RM, Yamauchi Y, Whittemore SR, Kaplan HJ. Enhanced induction of RPE lineage markers in pluripotent neural stem cells engrafted into the adult rat sub-retinal space. Invest Ophthalmol Vis Sci 2003;44:5417-22.
12. Tao W. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 2006;6:717-26.
13. Moshiri A, Close J, Reh TA. Retinal stem cells and regeneration. Int J Dev Biol 2004;48:1003-14.
14. Fischer AJ. Neural regeneration in the chick retina. Prog Retina Eye Res 2005;24:161-82.
15. Kelley MV, Turner JK, Reh TA. Retinoic acid promotes differentiation of photoreceptors in vitro. Development 1994; 120:2091-102.
16. Okada TS. Cellular metaplasia or transdifferentiation as a model for retinal cell differentiation. Curr Top Dev Biol 1980;16:349-80.
17. Thanos C, Emerich D. Delivery of neurotrophic factors and therapeutic proteins for retinal diseases. Expert Opin Bio Ther 2005;5:1443-52.
18. Schorderet DF, Manzi V, Canola K, et al. D-TAT transporter as an ocular peptide delivery system. Clin Exp Ophthalmol 2005;3:628-35.
19. Allen SJ, Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin Sci (Lond) 2006;110:175-91.
20. Chen H, Weber AJ. BDNF enhances retinal ganglion cell survival in cats with optic nerve damage. Invest Ophthalmol Vis Sci 2001;42:966-74.
21. Delyfer MN, Simonutti M, Neveux N, Leveillard T, Sahel JA. Does GDNF exert its neuroprotective effects on photoreceptors in the rd1 retina through the glial glutamate transporter GLAST? Mol Vis 2005;11:677-87.
22. Jiang LQ, Jorquera M, Streilein JW. Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci 1993;34:3347-54.
23. Martin KR, Quigley HA, Zack DJ, et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003;44:4357-65.
24. Pernet V, Hauswirth WW, Di Polo A. Extracellular signal-regulated kinase 1/2 mediates survival, but not axon regeneration, of adult injured central nervous system neurons in vivo. J Neurochem 2005;93:72-83.
25. Zhou Y, Pernet V, Hauswirth WW, Di Polo A. Activation of the extracellular signal-regulated kinase 1/2 pathway by AAV gene transfer protects retinal ganglion cells in glaucoma. Mol Ther 2005;12:402-12.
26. Bhutto IA, Kim SY, McLeod DS, et al. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:1544-52.
27. Mori K, Ando A, Gehlbach P, et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 2001;159:313-20.
28. Takahashi K, Saishin Y, Saishin Y, et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J 2003;17:896-98.
29. Kendall R.L., Wang G., Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-28.
30. Kendall R.L., Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993;90:10705-9.
31. Bainbridge JW, Mistry A, De Alwis M, et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 2002;9:320-6.
32. Mulligan RC. The basic science of gene therapy. Science 1993; 260:926-32.
33. Liu X, Brandt CR, Gabelt BT, Bryar PJ, Smith ME, Kaufman PL. Herpes simplex virus mediated gene transfer to primate ocular tissues. Exp Eye Res 1999;69:385-95.
34. Borras T, Gabelt BT, Klintworth GK, Peterson JC, Kaufman PL. Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo. J Gene Med 2001;3:437-49.
35. Loewen N, Fautsch MP, Teo WL, Bahler CK, Johnson DH, Poeschla EM. Long-term, targeted genetic modification of the aqueous humor outflow tract coupled with noninvasive imaging of gene expression in vivo. Invest Ophthalmol Vis Sci 2004;45:3091-8.
36. Liu X, Brandt CR, Gabelt BT, Kaufman PL. Gene therapy for glaucoma: anterior and posterior segment targets, delivery systems, constraints. In: Gramer E, Grehn F, eds. Pathogenesis and Risk Factors of Glaucoma. Berlin: Springer-Verlag; 1999:93-100.
37. Andrieu-Soler C, Bejjani RA, de Bizemont T, Normand N, BerEzra D, Behar-Cohen F. Ocular gene therapy: A review of nonviral strategies. Mol Vis 2006;12:1334-7.
38. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91:4407-11.
39. Ginsberg HS. The ups and downs of adenovirus vectors. Bull N Y Acad Med 1996;73:53-8.
40. Liu X, Hu Y, Filla MS, Gabelt BT, Brandt CR, Peters DP, Kaufman PL. The effect of C3 transgene expression on actin and cell adhesions in cultured HTM cells and on outflow facility in organ cultured monkey eyes. Mol Vis 2005;11:1112-21.
41. Hauswirth WW, Lewin AS, Zolotukhin S, Muzyczka N. Production and purification of recombinant adeno-associated virus. Methods Enzymol 2000;316:743-61.
42. Peel AL, Klein RL. Adeno-associated virus vectors: activity and applications in the CNS. J Neurosci Methods 2000;98:95-104.
43. Dudus L, Anand V, Acland GM, Chen SJ, Wilson JM, Fisher KJ, Maguire AM, Bennett J. Persistent transgene product in retina, optic nerve and brain after intraocular injection of Raav. Vision Res 1999;39:2545-53.
44. Guy J, Qi X, Muzyczka N, Hauswirth WW. Reporter expression persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve. Arch Ophthalmol 1999;117: 929-37.
45. Jacobson SG, Boye SL, Aleman TS, et al. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther 2006;17:845-58.
46. Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol 1999;73:8549-58.
47. Loewen N, Fautsch MP, Peretz M,et al. Genetic modification of human trabecular meshwork with lentiviral vectors. Hum Gene Ther 2001;12:2109-19.
48. Doi K, Kong J, Hargitai J, Goff SP, Gouras P. Transient immunosuppression stops rejection of virus-transduced enhanced green fluorescent protein in rabbit retina. J Virol 2004;78:11327-33.
49. Song B, Javanbakht H, Perron M, Park D, Stremlau M, Sodroski J. Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J Virol 2005; 79:3930-7.
50. Saenz DT, Teo W, Olsen JC, Poeschla EM. Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins. J Virol 2005;79:15175-88.
51. Ralph GS, Binley K, Wong LF, Azzouz M, Mazarakis ND. Gene therapy for neurodegenerative and ocular disease using lentiviral vectors. Clin Sci (Lond) 2006;110:37-46.
52. Zhang Y, Schlachetzki F, Li JY, Boado RJ, Pardridge WM. Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol Vis 2003;9:465-72.
53. Chung DC, Wei Z, Bennett J, Scheie FM. In vivo non-viral gene transfer to retinal ganglion cells. Invest Ophthalmol Vis Sci 2006;47:ARVO E-Abstract 836.
54. Ishikawa H, Takano M, Matsumoto N, Sawada H, Ide C, Mimura O, Dezawa M. Effect of GDNF gene transfer into axotomized retinal ganglion cells using in vivo electroporation with a contact lens-type electrode. Gene Ther 2005;12:289-98.
55. Wells DJ. Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther 2004;11:1363-9.
56. Hangai M, Tanihara H, Honda Y, Kaneda Y. Introduction of DNA into the rat and primate trabecular meshwork by fusogenic liposomes. Invest Ophthalmol Vis Sci 1998;39:509-16.